TET2 and hematologic disorder: TET2 mutations enhance hematopoietic stem cell (HSC) self‐renewal, which subsequently drives the development of various hematologic malignancies together with mutations in DNMT3A, JAK2, additional sex combs‐like 1, serine and arginine rich splicing factor 2, splicing factor 3b subunit 1, nucleophosmin 1, fms‐related receptor tyrosine kinase 3, B cell lymphoma 6 (Bcl6), tumor protein p53, and KRAS [331, 333, 350‐352].